Germany confirms first locally acquired case of Sindbis virus in Baden-Württemberg

Detection of local infection in Baden-Württemberg

The Robert Koch Institute in Berlin announced Germany's first confirmed case of locally acquired Sindbis virus disease in a human. The patient affected by the mosquito-borne illness is a 60-year-old man residing in the state of Baden-Württemberg. Health researchers had previously discovered the Sindbis virus in mosquito populations located around the city of Weinheim. Subsequent screenings in the Weinheim area had also detected specific antibodies in blood donors, indicating that individuals in the region had encountered the virus in previous years. The confirmation announced by federal health authorities marks the first time that the pathogen was identified in direct connection with an active human illness contracted within Germany.

Diagnosis and timeline of the case

The infected individual in Baden-Württemberg initially fell ill on 12 July 2026. The patient resides in an urban district known to have established populations of the invasive Asian tiger mosquito, known scientifically as Aedes albopictus. Due to the presence of this specific mosquito species and the patient's initial symptoms, attending physicians initially ordered laboratory testing for Chikungunya virus. Following that preliminary assessment, clinicians broadened the differential diagnostic testing to evaluate other vector-borne agents, including Sindbis virus. That expanded diagnostic investigation resulted in the definitive laboratory detection of Sindbis virus in September 2026.

Pathogen transmission and clinical profile

Sindbis virus, or SINV, is an infectious pathogen that circulates primarily among wild bird species and spreads through mosquito vectors. Geographically, the virus is known to occur in parts of Northern Europe, Africa, Asia, and Australia. Public health records show no evidence of transmission from human to human. When an infected mosquito bites a human host, the individual can develop the illness known as Sindbis fever. Typical manifestations of the infection include sudden fever, an itchy skin rash, and intense joint pain. Because these symptoms mirror the clinical presentation of Chikungunya virus disease, laboratory verification is necessary to distinguish between the two infections.

Prognosis, treatment, and clinical guidance

Public health officials classify Sindbis fever as a non-life-threatening infection. The characteristic fever and skin rash usually clear within one to two weeks after onset. The severe joint pain, however, can linger for many weeks or several months, frequently interfering with work and daily activities. Medical science currently offers no specific antiviral therapy or vaccine against Sindbis virus, meaning treatment is limited to symptom management with pain-relieving and anti-inflammatory medications. Preventative recommendations focus on avoiding mosquito bites through the use of long clothing, insect repellent sprays, and mosquito nets. The Robert Koch Institute stated that the Baden-Württemberg case confirms human infections are to be expected wherever the virus is established in local wild birds and mosquitoes, advising medical practitioners to include Sindbis virus in diagnostic evaluations for patients presenting with fever, rash, and severe joint pain during mosquito season.